Drug Makers Agree To Freeze Some Prices, Cut Others In Thailand
This article was originally published in PharmAsia News
Executive Summary
Drug makers operating in Thailand agreed to a six-month freeze of prices on some drugs and a 5 percent to15 percent reduction on other medicines. The head of Thailand's Internal Trade Department said both domestic and foreign drug makers would be submitting to him details on the price cuts they plan to make. Hospital operators are balking at heeding the same price-cut call by the country's commerce minister, who issued the request to all manufactures in response to reports of a high inflation rate in the country. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.